NOXXON Pharma AG
Edit

NOXXON Pharma AG

http://www.noxxon.com/
Last activity: 31.01.2022
Categories: PlatformMedtechManagementDevelopmentDataCareBuildingBioTechAlternative
NOXXON Pharma is a clinical-stage biopharmaceutical company whose core focus is on improving cancer treatment by targeting the tumor microenvironment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.
Mentions
37
Total raised: $66.34M
Founded date: 1998
Twitter
LinkedIn

Investors 4

Funding Rounds 6

DateSeriesAmountInvestors
29.12.2021-$19.18M-
30.04.2021-$1.45M-
06.08.2019-$1.12M-
09.05.2017-$1.09M-
12.10.2010Series D$2.78M-
27.05.2010-$40.72M-

Mentions in press and media 37

DateTitleDescriptionSource
31.01.2022NOXXON ANNOUNCES EUR2.375 MILLION FINANCING UNDER AGREEMENT ...Berlin, Germany - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused...marketscre...
29.12.2021NOXXON Pharma N : secures Euro 17 million expansion of equit...NOXXON SECURES €17 MILLION EXPANSION OF EQUITY-LINKED FACILITY WITH ATLAS TO ADVANCE NOX-A12 IN GLI...marketscre...
15.12.2021NOXXON Pharma N : announces results of the extraordinary gen...NOXXON ANNOUNCES RESULTS OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Berlin, Germany, Dec...marketscre...
15.12.2021NOXXON Pharma N : to participate in banking and investor con...NOXXON TO PARTICIPATE IN BANKING AND INVESTOR CONFERENCES IN JANUARY AND FEBRUARY 2022 Berlin, Ger...marketscre...
22.11.2021NOXXON: New Phase 1/2 data on NOX-A12 & radiotherapy com...NOXXON: NEW PHASE 1/2 DATA ON NOX-A12 & RADIOTHERAPY COMBINATION IN BRAIN CANCER PRESENTED AT T...marketscre...
15.11.2021NOXXON Pharma N : announces convocation of an Extraordinary ...NOXXON ANNOUNCES CONVOCATION OF AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Appointment of Br...marketscre...
09.11.2021NOXXON to present at the third edition of Investir Day on No...NOXXON TO PRESENT AT THE THIRD EDITION OF INVESTIR DAY ON NOVEMBER 23 IN PARIS, FRANCE Berlin, Ger...marketscre...
03.11.2021NOXXON provides update on timing for upcoming trials of NOX-...NOXXON PROVIDES UPDATE ON TIMING FOR UPCOMING TRIALS OF NOX-A12 IN PANCREATIC AND BRAIN CANCER Ber...marketscre...
27.10.2021Experienced financial executive, Bryan Jennings, joins NOXXO...EXPERIENCED FINANCIAL EXECUTIVE, BRYAN JENNINGS, JOINS NOXXON AS CFO Berlin, Germany, October 27, ...marketscre...
19.10.2021NOXXON Pharma N : announces planned expansion of Phase 1/2 N...NOXXON ANNOUNCES PLANNED EXPANSION OF PHASE 1/2 NOX-A12 BRAIN CANCER TRIAL Berlin, Germany, Octobe...marketscre...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In